Compare Novo Nordisk A/S (NVO) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Direxion Daily TSLA Bull 2X Shares trades at $10.4 (market cap $3.97B). The key difference: Novo Nordisk A/S is far larger — about 41.6× Direxion Daily TSLA Bull 2X Shares's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| NVO | TSLL | |
|---|---|---|
Market Cap | $165.31B | $3.97B |
Volume | 11,432,838 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $23.03 |
52-Week Low | $35.29 | $6.74 |
Typical Hold Time | 116 Days | 15 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
TSLL, a leveraged ETF tracking Tesla, trades at $10.01, down 1.38% amid neutral technical signals. Moving averages suggest a bullish trend, but RSI indicates overbought conditions. The ETF lacks traditional financial ratios due to its structure, and recent news highlights its volatility tied to Tesla's Cybercab event.
Outlook hinges on Tesla's performance, offering amplified gains but high risk from daily rebalancing. Investors face significant volatility and potential decay, requiring careful risk management given the leveraged nature and dependence on Tesla's stock movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
